logo-loader
RNS
ValiRx PLC

ValiRx PLC - Director/PDMR Shareholding

RNS Number : 6317P
ValiRx PLC
18 February 2021
 

("ValiRx", the "Company" or the "Group")

 

Director/PDMR Shareholdings

 

London, UK - ValiRx plc (AIM:VAL), a clinical stage drug development company, announces that it has received notifications on 18 February 2021 of the following share purchases by certain Directors and PDMRs of the Company.

 

Name

Number of shares purchased

Purchase price

Date of purchase

Number of shares held prior to purchase

Number of shares held following purchase

Percentage shareholding of issued share capital following purchase

Kevin Cox

(Director)

 

22,000

22.25p

 

17/02/2021

250,333

272,333

0.42%

Gerry Desler

(Director)

 

22,000

22.75p

 

18/02/2021

81,668

103,668

0.16%

Martin Lampshire

(Director)

 

44,000

22.70p

18/02/2021

-

44,000

0.07%

Mark Treharne

(PDMR)

 

6,095

22.78p

17/02/2021

-

6,095

0.01%

 

Exercise of Warrants

 

Furthermore, the Company received notifications on 18 February 2021 for the exercise of warrants over 166,666 new ordinary shares in the Company at an exercise price of 13p each ("New Ordinary Shares") by Suzanne Dilly and Kevin Alexander, both Directors of the Company. Details of the exercise are set out in the table below.

 

Name

Number of warrants exercised

Purchase price

Number of shares held prior to purchase

Number of shares held following exercise

Percentage shareholding of issued share capital following exercise

Suzanne Dilly

 

83,333

13.00p

233,335

316,668

0.49%

 

Kevin Alexander

 

83,333

13.00p

167,500

250,833

0.39%

 

Total Voting Rights

 

The Company had previously applied to list these 166,666 ordinary shares as part of the block listing of 9,034,732 ordinary shares of 0.1 pence each in the Company ("Ordinary Shares") which was announced on 19 August 2020. They were admitted to trading on AIM on 24 August 2020.

 

The total voting rights of the Company comprise 65,049,156 Ordinary Shares which may be used by shareholders (and others with notification obligations) as the denominator for the calculations by which they will determine whether they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

 

 

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014. The Directors of the Company take responsibility for this announcement.

 

Ends

 

For further information please contact:

 

ValiRx plc

Tel: +44 (0) 2476 796496

www.valirx.com

Suzanne Dilly, CEO

Suzanne.Dilly@valirx.com

 

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner / Ludovico Lazzaretti

 

Tel: +44 (0) 20 7213 0880

 

Peterhouse Capital Limited (Sole Broker)

Duncan Vasey / Lucy Williams / Eran Zucker

 

Tel: +44 (0) 20 7469 0930

 

Optimum Strategic Communications

Supriya Mathur/ Shabnam Bashir

 

Tel: +44 (0) 20 8148 3040

valirx@optimumcomms.com

 

 

About ValiRx plc

ValiRx accelerates the development of treatments in oncology and women's health to improve patient lives. We provide the scientific, financial and commercial framework towards enabling rapid translation of innovative science into clinical development.

 

With our extensive and proven experience in research and drug development, we select and incubate promising novel drug candidates and guide them through an optimised process of development, from pre-clinical studies to clinic and investor-ready assets.

 

Integrating science and business

We connect diverse disciplines across scientific, technical and commercial domains, with the aim of achieving a more streamlined, less costly, drug development process.  We work closely with our selected collaborators and leverage the combined expertise required for science to advance.

 

Lead candidates from our portfolio are out-licensed or partnered with investors through ValiRx subsidiary companies for further clinical development and commercialisation. https://www.valirx.com/

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Kevin Cox

b) Gerry Desler

c) Martin Lampshire

d) Mark Treharne

 

2

Reason for notification

 

a.

Position/Status

a) Director

b) Director

c) Director

d) PDMR

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

 

213800VQKB9SJCQDET40

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Ordinary Shares

 

 ISIN: GB00BLH13C52

b.

Nature of the transaction

On market Purchase

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

a)  £ 0.22250

b) £ 0.22745

c) £ 0.22700

d) £ 0.22780

 

a) 22,000

b) 22,000

c) 44,000

d)   6,095

 

 

 

d.

Aggregated information

- Aggregated Volume

- Price

 

94,095

 

£0.22610 (weighted average price) 

e.

Date of the transaction

a) 17/02/2021

b) 18/02/2021

c) 18/02/2021

d) 17/02/2021

 

f.

Place of the transaction

London, UK

 

                 

 

Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014

1

Details of the person discharging managerial responsibilities/person closely associated

a.

Name

a) Suzanne Dilly

b) Kevin Alexander

 

2

Reason for notification

 

a.

Position/Status

a) Director

b) Director

b.

Initial notification/

Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a.

Name

ValiRx PLC

b.

LEI

 

213800VQKB9SJCQDET40

 

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a.

Description of the financial instrument, type of instrument

Identification Code

Warrants over new ordinary shares

 

 ISIN: GB00BLH13C52

b.

Nature of the transaction

Exercise of warrants over new ordinary shares at an exercise price of 13p per share

c.

Price(s) and volume(s)

 

 

 

 

 

 

Price(s)

Volume(s)

 

a) £0.13

b) £0.13 

83,333

83,333

 

 

d.

Aggregated information

- Aggregated Volume

- Price

 

166,666

£0.13 

e.

Date of the transaction

18/02/2021

f.

Place of the transaction

London, UK

 

                 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBUGDDLXBDGBI
NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read